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Abstract Radioembolization with 90Y-loaded microspheres
is increasingly used in the treatment of primary and secondary
liver cancer. Technetium-99 m macroaggregated albumin
(MAA) scintigraphy is used as a surrogate of microsphere
distribution to assess lung or digestive shunting prior to ther-
apy, based on tumoral targeting and dosimetry. To date, this
has been the sole pre-therapeutic tool available for such eval-
uation. Several dosimetric approaches have been described
using both glass and resin microspheres in hepatocellular car-
cinoma (HCC) and liver metastasis. Given that each product
offers different specific activities and numbers of spheres
injected, their radiobiological properties are believed to lightly
differ. This paper summarizes and discusses the available
studies focused on MAA-based dosimetry, particularly con-
centrating on potential confounding factors like clinical con-
text, tumor size, cirrhosis, previous or concomitant therapy,
and product used. In terms of the impact of tumoral dose in
HCC, the results were concordant and a response relationship
and tumoral threshold dose was clearly identified, especially
in studies using glass microspheres. Tumoral dose has also
been found to influence survival. The concept of treatment
intensification has recently been introduced, yet despite sev-
eral studies publishing interesting findings on the tumor dose-
metastasis relationship, no consensus has been reached, and
further clarification is thus required. Nor has the maximal
tolerated dose to the liver been well documented, requiring
more accurate evaluation. Lung dose was well described, de-
spite recently identified factors influencing its evaluation, re-
quiring further assessment.Conclusion: MAA SPECT/CT do-
simetry is accurate in HCC and can now be used in order to
achieve a fully customized approach, including treatment in-
tensification. Yet further studies are warranted for the metas-
tasis setting and evaluating the maximal tolerated liver dose.
Keywords Selective internal radiation therapy . Predictive
dosimetry . Prognosis
Introduction
Radioembolization with yttrium 90 (90Y)-loaded glass or resin
microspheres is increasingly used in the treatment of primary
and secondary liver cancers. In colorectal metastatic disease,
its efficacy has been proven by two randomized studies [1, 2].
In hepatocellular carcinoma (HCC), the clinical results of this
technique in large patient cohorts were encouraging, especial-
ly for those with portal vein thrombosis (PVT), though no
randomized studies are currently available [3–7]. The efficacy
of radioembolization in HCC patients with PVT had, howev-
er, already been demonstrated a long time ago using 131I-
lipiodol [8], thus providing proof of the benefits of
radioembolization in this context.
Simulation is always performed prior to injecting micro-
spheres, consisting of twomandatory and complementary pro-
cedures: diagnostic angiography and 99mTc macroaggregated
albumin (MAA) scintigraphy. Diagnostic angiography is used
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to identify digestive arteries arising from the hepatic artery,
with coil embolization when necessary, and to select the best
catheter position for tumoral targeting. Cone-beam computed
tomography (CT) is a valuable new procedure that can be
performed during the angiography to aid in digestive vascu-
larization recognition, as well as perfused tissue and tumoral
targeting evaluation. While MAA scintigraphy was initially
used solely for lung-shunt evaluation, it can also aid in diges-
tive shunt recognition and dosimetric evaluation.
The goal of radioembolization is to deliver a tumoricidal
absorbed dose to tumors while sparing the healthy liver tissue
[9, 10]. To achieve the best efficacy and lowest toxicity pro-
file, the tumor absorbed dose (TD) and that absorbed by
healthy injected liver tissue (HILD) should be evaluated prior
to commencing therapy.
From a radiobiological point of view, selective internal radi-
ation therapy (SIRT) and external beam radiotherapy (EBRT)
are critically different techniques [11]. This is primarily due to
significant differences in dose distribution, which is heteroge-
neous in SIRT, dependent on the biodistribution of the thera-
peutic agent, and homogeneous in EBRT. The radiation expo-
sure rate also varies between the techniques, with lower rates in
SIRT compared to EBRT. The absorbed doses calculated in Gy
for SIRT and EBRT are therefore not equivalent, with 1 Gy in
EBRT not producing the same radiobiological disorders as
1 Gy in SIRT. A direct comparison of the value of absorbed
doses between SIRT and EBRT is therefore impossible.
Nevertheless, only limited data is available concerning tu-
mor dosimetry and the maximal tolerated healthy liver dose
while using 90Y-loaded microspheres. Two kinds of dosimet-
ric approaches can be used. Pre-therapeutic dosimetric evalu-
ation can be performed using MAA single-photon emission
CT (SPECT)/CT, presenting the major advantage of being
available prior to 90Y-loaded microsphere injection, and also
affording the possibility of directly influencing the treatment
schedule. Post-therapeutic dosimetric evaluation, after 90Y-
loaded microsphere injection, can be performed using either
90Y bremsstrahlung SPECT/CT or direct 90Y positron emis-
sion tomography (PET).
This paper sought to discuss the confounding factors that
may have an impact on MAA dosimetry and the clinical do-
simetric impact of MAA SPECT/CT-based dosimetry in
radioembolization.
Dosimetric tools and endpoints
Evaluation of the physical absorbed dose
To date, several different dosimetric approaches have been
described using both glass and resin microspheres in HCC
and liver metastasis [12]. The main approaches seen are the
classical medical internal radiation dose (MIRD) technique,
Monte Carlo simulation, and kernel point evaluation. These
provide the physically absorbed dose: D.
The MIRD approach
The most widely used method is MIRD, assuming a homoge-
neous distribution of spheres.
As microspheres are not biodegradable and remain trapped
in the vessels following initial embolization, the effective half-
life is assumed to be equal to the physical half-life of yttrium
90.
The absorbed dose, D (in Gy), in an organ of mass, M (in
Kg), with an organ activity, A (in GBq) of 90Y, is then calcu-
lated using the following simplified MIRD equation:
D Gyð Þ ¼ A GBqð Þ:50=M Kgð Þ
Doses can be calculated for different compartments, espe-
cially tumor, liver, healthy liver, and lung tissues.
Doses are calculated at the voxel level or expressed as the
mean dose of a compartment.
The activity in each compartment, namely the injected liv-
er, tumor, healthy injected liver, and lungs, is typically evalu-
ated by means of MAA scintigraphy.
The compartment volumes, namely the injected liver, tu-
mor, healthy injected liver, and non-injected liver, can be mea-
sured using CT or cone-beam CT.
More recently, it has been shown that volumes can be ac-
curately measured using SPECT/CT. It is well known that
SPECT alone cannot achieve accurate volume measurement,
as it depends on the threshold used for the volume of interest
(VOI) delineation, required for evaluating the structure of in-
terest. A phantom study has, however, demonstrated that
SPECT/CT volume measurement can be accurate if the
thresholding is guided by an anatomical visualization of the
VOI on the fusion images, producing a mean error rate <7 %
[13].
Given the wide variations possible in hepatic vasculariza-
tion in this context, the use of MAA SPECT/CT for volume
measurement offers the advantage of providing a more func-
tional evaluation of the volume that is truly perfused [13].
We therefore conclude that two methods are available for
tumor segmentation, offering significantly different results in
terms of dosimetric evaluation. The first is morphological,
with the tumor VOI delineated by means of CT, and then
copied onto the SPECT imaging (or SPECT/CT) for count
evaluation. In this situation, the tumor dose takes into account
cold areas of necrosis. This method provides a relatively
underestimated tumor dose. The second method, based only
on SPECT (or SPECT/CT), is more functional. In this situa-
tion, only the hypervascularized part of the tumor is taken into
account, with its dosimetry providing the basis of the tumor
dosimetry, excluding tumor necrosis. This method provides a
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relatively overestimated tumor dose in comparison with the
former morphological technique. An example of tumor seg-
mentation with SPECT/CT is provided in Fig. 1.
Drawbacks of the MIRD approach
MIRD does not, however, take into consideration the hetero-
geneity of dose distribution. It also disregards how the
crossfire phenomenon affects the absorbed dose; namely, the
irradiation of the tumor related to microspheres located in the
surrounding healthy injected liver, and vice versa.
These two drawbacks can be overcome with the Monte
Carlo simulation. Using a BMonte Carlo code,^ this method
accurately simulates the amount of energy deposed in tissue
by a punctual source of radioactivity, considering both the
random nature of particle interactions in tissue and tissue het-
erogeneity. However, its computing time is very long, up to
several days, thus limiting its use.
The Dose-point Kernel method has been developed as a
way of reducing this computing time. Rather than simulating
energy deposition, this method only estimates the amount de-
posed in tissue by a punctual source of radioactivity, assuming
a homogeneous tissue. This approach therefore takes into ac-
count the crossfire phenomenon, yet heterogeneity is still a
problem, and the technique is consequently not routinely used.
We should not forget, however, that the above methods
may be implemented in the future to further improve dosimet-
ric evaluation, especially in difficult cases where MIRD may
be insufficient.
Tumor size has a direct impact on SPECT/CT radioactivity
quantification, namely the count of detected radioactive
disintegration, carrying a risk of partial volume effect for le-
sions that are up to two times smaller than the spatial resolu-
tion of the gamma camera. This observation results in an un-
derestimation of the quantification and thus of the calculated
absorbed dose. The partial volume effect has been known to
occur with lesions under 3 cm in size and constitutes a major
risk for any smaller than 2 cm. This is why several teams
exclude tumors smaller than 2 cm from dosimetric evaluation
[12].
In cases of multifocal or infiltrative disease, tumor delinea-
tion may be difficult to perform or even impossible to achieve,
and it may be impossible to accurately evaluate dosimetry,
whichever method is used (MIRD, Monte Carlo or Kernel).
Biologically effective dose calculation
The biologically effective dose (BED) can be implemented
using the three principal dosimetric approaches mentioned
above, namely MIRD, Monte Carlo, and kernel point. BEDs
are based on correcting the physically absorbed dose D by
means of radiobiological parameters. One of the advantages
of this approach is that doses expressed as BED are usually
comparable between all radiation therapy types, especially
EBRT and SIRT.
BED is then calculated as below [14]:
BED ¼ Dþ D2 : λ= μþ λ½ ð Þ : 1= α=β½ ð Þ
Parametersα andβ are related to specific tissue parameters
in terms of cell radiosensitivity, with α related to lethal dam-
age and β to sublethal damage. The μ is linked to the repair of
Fig. 1 Tumoral VOI delineation
using MAA SPECT/CT. a) CT
slide: huge tumor of 12.1×17.4×
9.7 cm with a large part of central
necrosis. b) MAA/SPECT CT
tumor volume segmentation.
Based on MAA SPECT/CT,
tumor volume is only 900 cc due
to a large part of necrosis. Using
CT segmentation, tumor volume
is 1310 cc. Doing the hypothesis
of absence of radioactivity uptake
in necrosis, tumor dose based on
MAA segmentation (excluding
necrosis volume) is 1.45 fold
higher than tumor dose based on
CT segmentation (including
necrosis volume)
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sublethal damage (μ=ln [2]/ T ½, repair) and λ is the biologi-
cally effective decay constant. To date, the most widely used
α/β ratios for SIRT are 10 and 2.5 Gy for tumor and normal
liver tissue, respectively. Themost widely used values for T1/2,
rep are 1.5 and 2.5 hours for tumor and normal liver tissue,
respectively [14, 15].
Yet these parameters result from EBRT techniques with a
specific irradiation configuration of dose, dose rate, and frac-
tionation. New parameters must now be specifically defined
for SIRT configurations, including the isotope and specific
activity used, if we are to obtain a dosimetric evaluation that
is comparable between each type of radiation therapy.
In the future, the use of BEDs could be of great interest, as
we would be able to correct radiobiological parameters for
several clinical parameters, like hypoxia, etc. Another out-
come could be the possibility of implementing fully personal-
ized definition parameters based on the patient’s biological
status and tumor and liver genomic status.
Dosimetric endpoints
The dosimetric endpoints vary depending on the product used,
i.e., resin or glass microspheres.
Dosimetric endpoints for resin microspheres
Two rules governing activity definition are now available for
resin microspheres: the body surface area method (BSA) and
the partition model.
For the BSA method (results in m2), the activity to be
injected (IA) is calculated using the following formulae:
For whole-liver injection:
IA GBqð Þ ¼ BSA–0:2ð Þ þ fractional tumor involvement
For lobar injection:
IA GBqð Þ ¼ BSA – 0:2½ ð þ fractional tumor involvement
% of treated liverð Þ
The partition model, initially described by Ho et al. [16],
has been declared the recommended choice, according to an
expert panel, for HCC cases with delineable tumors [9]. This
model consists in performing a dose evaluation of the tumor
and healthy liver tissue. In the past, the tumor and healthy liver
uptake were calculated using the ratio Br^ of tumor uptake /
non-tumor uptake, measured on planar MAA scintigraphy.
In current practice, tumor and non-tumor uptake are direct-
ly measured by SPECT or SPECT/CT.
Experts recommend a tumor dose (TD) of at least 120 Gy,
whereas the dose to the healthy liver should not exceed 50-
70 Gy, despite the lack of rigorous documentation of this limit
[9]. In cases involving non-delineable tumors, the BSA meth-
od is used.
With regard to lung shunting fraction (LSF), the injected
activity was adapted. According to SIRtex recommendations
[17], 90Y-loaded resin microspheres are contra-indicated for
cases exhibiting an LSF exceeding 20 %. The prescribed ac-
tivity is reduced by 40 % for an LSF between 15 and 20 %,
and by 20% for one between 10 and 15%. The full prescribed
activity can be injected for an LSF <10 %.
Lung dose can also be directly calculated using the parti-
tion model for lung-dose estimation described by Ho et al.
[16], using the following MIRD simplified formula:
L D Gyð Þ ¼ IA GBqð Þ: LSF : 50
where IA is the injected activity of 90Y-loaded microspheres
and LSF is the lung shunting fraction, and with the assumption
of a uniform dose distribution, 1 kg lung mass, and that 1 GBq
of 90Y delivers 50 Gy in a 1 kg mass.
A limit of 30 Gy is now more currently used in calculating
lung dose, rather than the SIRtex recommendation regarding
activity reduction based on LSF.
Dosimetric endpoints and glass microspheres
With glass microspheres, the objective is to deliver a radiation
dose of 120±20 Gy to the injected liver volume (ILD), calcu-
lating the dose based on the accepted simplified MIRD for-
mula given below [18]:
IL D Gyð Þ ¼ IA GBqð Þ: 1−LSFð Þ: 50= M Kgð Þ
where IA represents the activity to be injected, LSF the lung
shunting fraction, and M the mass of liver volume to be
treated.
Lung dosimetry is also evaluated, assuming a lung mass of
1 kg, using the same Ho et al. simplified MIRD formula given
in the previous paragraph.
The recommended maximal lung dose is 30 Gy for one
treatment session and 50 Gy as a cumulative dose [18].
MAA as a microsphere surrogate and confounding
factors
The physical properties of MAA and microspheres
MAA is made up of biodegradable particles, whose size are
not well calibrated and are estimated to be between 10 to
150 μm. The majority, 90 %, measure between 10 and
40 μm and 1–2 % measure under 15 μm.
For microsphere simulation, between 150 and 250 MBq of
99mTc-MAA are typically injected into the hepatic artery,
along with approximately 0.5 × 106 MAA particles [19]. As
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a comparison, we injected approximately 2 × 106 spheres for
1.5 GBq of glass microspheres on Day 3 post-calibration, and
around 30 × 106 spheres for 1.5 GBq of resin microspheres.
Labeling proved to not be highly accurate, with the pres-
ence of 99mTc possible. There is some uncertainty with regard
to the stability of MAA after preparation, though no studies
have thus far proven its instability. Labeling instability after
injection has, however, already been reported [20], and the
literature recommends performing the MAA scan as soon as
possible after injection.
Despite their being approximately the same size, the spe-
cific activities and number of spheres injected differ between
these two products. The mean size of glass microspheres is 25
±5 μm and their specific activity is 2500 Bq/sphere. For resin
microspheres, the mean size is 32±10 μm with a specific
activity of only 50 Bq/sphere. Even if no comparative study
is available, resin microspheres theoretically produce a stron-
ger embolic effect due to the higher number of spheres
injected for the same activity, and the discrepancies between
MAA and resin microsphere distribution may be even more
frequent.
On the other hand, Bilbao et al. reported contrasting
findings when performing arterial injection of resin mi-
crospheres, which resulted in no microscopic signs of
ischemia in healthy pig liver tissue following injection
until stasis, with only 20 % of the vascularization clas-
sically arising from the hepatic artery [21]. Neverthe-
less, this observation using healthy tissue cannot be ex-
trapolated to tumors, where 80 % of the vascularization
classically arises from the hepatic artery, involving im-
mature neovessels. The potential embolic and ischemic
effect of resin microspheres in some tumors is still a
matter of debate. This potential emphasizes the value
of a slow injection of resin microspheres, accompanied
by sequential angiographic monitoring in order to pre-
vent stasis, which has been proven to be the primary
cause for stopping delivery of resin microspheres before
the full planned activity can be injected [22]. This em-
bolic effect is thought to be stronger in small metastatic
lesions [23], and probably produces an impact on ther-
apeutic effectiveness. The potential embolic effect of
resin microspheres thus only means that MAA-based
dosimetric evaluation may be inaccurate in this context.
Due to this significant difference in specific activity
and thus in the number of microspheres necessary for
the same injected activity, the radiobiological properties
of resin and glass microspheres are believed to differ
[24, 25], requiring separate analysis [26]. A recent study
based on microsphere distribution modeling clearly
demonstrated that the different radiobiological effects
of glass and resin microspheres were indeed related to
differences in the specific activity and number of
spheres injected [25].
Confounding factors
Despite the absence of a specific study on this subject, it is
more than likely that several confounding factors, other than
microsphere type, may have an impact on the reproducibility
between 99mTc-MAA and microsphere distributions, includ-
ing tumor type (e.g., primary or metastasis ), tumor vascular-
ization, tumor size, prior therapy, MAA injection parameters,
and angiographic considerations such as catheter position and
vasoactive arterial status.
Tumor type
In an HCC context, there are typically one or several large
lesions that receive frequent first-line treatment. The mean
reported percentage of MAA injected uptake by HCC is
32 %, even exceeding 90 % in large and highly vascularized
tumors [27]. Tumor-to-non-tumor uptake ratios are usually
high, with a mean of 7.2 [27].
For metastases, the clinical situation differs, manifesting as
multifocal disease with generally smaller lesions in patients
who have received limited or no previous treatment, with var-
iable vascularization levels. In one study by Van deWiele, the
mean MAA incorporated by lesions was only 1.5 % [19]. The
tumor-to-non-tumor ratio proved to be typically lower, with a
mean value of only 1.7 reported in one study [28].
Tumor size
As the risk of reflux is reportedly higher in small tumors [23],
MAA and microsphere distribution may be discordant in this
context.
Prior therapy
Prior therapy may induce arterial disorders and weaknesses.
This is especially the case for patients who have received
chemoembolization or antiangiogenic drugs. In this context,
the reproducibility of the two angiographic procedures, the
first being diagnostic and the second therapeutic, may be im-
paired due to arterial microlesions induced by the first angi-
ography. Studies have already described high discordance be-
tween MAA and microsphere distribution in this context [29].
The parameters of MAA injection
There are currently no clear recommendations regarding the
MAA injection process. Guidelines indicate slow injection is
better, ideally lasting 20–30 seconds, into a volume of suffi-
cient size, ideally greater than 5 ml, to best mimic microsphere
infusion, with glass microspheres requiring 20 cc, and resin
requiring even more.
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Angiographic considerations
The most relevant and widely recognized angiographic con-
sideration is the exact location of MAA and microsphere in-
jection. Both products must be injected into exactly the same
position, i.e. the same vessel, the same distance from the tip of
the catheter and bifurcations, and the same orientation in the
vascular lumen.
Typically, good reproducibility between MAA and micro-
sphere biodistribution is impossible if the MAA is injected
into the common hepatic artery and the microspheres into
the right or left hepatic artery. This situation can occur in cases
of bilateral disease, with one work up involving MAA injec-
tion into the common hepatic artery followed by two sequen-
tial lobar microsphere injections. In this situation, the liver
lobe with the most significant tumor involvement can divert
the arterial flow.
This is also the reason why, no matter which artery is se-
lected (right or left hepatic artery), the exact position of the
catheter, namely the distance from the tip of the catheter and
bifurcations, must be the same. The angle of the catheter may
also influence MAA/microsphere distribution.
Nevertheless, even when using the same intended catheter
positioning for 99mTc-MAA and microsphere injections, the
product distribution can at times differ. This observation was
made by Chiesa et al. [12] in 6.8 % of 29 HCC patients treated
with glass microspheres, as well as by Jiang et al. [30] in 8.6%
of 81 treatments with resin microspheres. This point under-
lines the observation that confounding factors potentially
influencing particle distribution must be analyzed with great
care in order to avoid erroneous conclusions or an overgener-
alization of results obtained in a specific situation.
Another key angiographic consideration, which has not
been well documented in the scientific literature despite its
potentially major impact on MAA and microsphere distribu-
tion, is the vasoactive status of the hepatic artery at the time of
injection. When performing a dosimetric simulation with
MAA, we work under the hypothesis that a diagnostic angi-
ography is identical to a therapeutic one, meaning that the
arteries concerned have the same vasoactive status. In reality,
this is not necessarily the case, as diagnostic angiographies are
typically longer, at times involving aggressive measures like
coil embolization that may induce vasospasm.
Using different catheters with varying rigidities can also
impact the vasoactive arterial status. Figure 2 provides an
example of discordance between MAA and microsphere dis-
tribution associated with an arterial spasm that occurred dur-
ing the MAA injection but not during microsphere injection,
owing to differing catheters.
Despite these limitations, MAA-based dosimetry is none-
theless the only available tool for pre-therapy use that may
directly impact the treatment schedule. Kao et al. [31] demon-
strated a strong correlation between predictive 99mTc-MAA
SPECT/CT tumor dose and post-radioembolization yttrium-
90 PET dose with resin microspheres. Their experiment was
conducted in near-ideal dosimetric conditions, involving well-
delineated tumors >2 cm and with a T/NT ratio >2, and thus
underlined this dosimetric technique’s great value. BothMAA
and PET dosimetry were performed in 23 patients, primarily
presenting with HCC (19 cases). The median relative error
between both dosimetric evaluations was only 3.8 % (95 %
confident interval [CI]: -1.2 % to+13.2 %), with a trend to-
wards a slight tumor dose overestimation observed with
99mTc-MAA SPECT/CT. This study confirmed the value of
MAA as a surrogate to microsphere injection when confound-
ing factors are controlled.
Lung shunting evaluation and lung dosimetry
Lung shunting evaluation
The lung shunting fraction (LSF) is defined as the ratio of lung
counts to total counts, with extra-hepatic counts considered as
gastroduodenal ones. The counts are currently evaluated by
means of anterior and posterior planar scan and geometric
methods.
In earlier studies [32, 33], LSF was evaluated by means of
99mTc-MAA planar scan. A more extensive study then evalu-
ated 402 patients, 377 with HCC and 25 with liver metastasis
[33], revealing higher LSF in the HCC patients (median:
7.6 %; min.: <1 %, max.: 75.4 %) than metastatic (median:
4.7 %; min.: <1 %, max.: 23.9 %). For HCC, lung shunting
correlated with tumor size (p <0.0001) and tumor vascularity,
as assessed by angiography.
Lung dosimetry
Radiation pneumonitis after 90Y-loaded resin microsphere im-
plantation was first described by Leung et al. in 1995 [34].
Five out of the total 80 patients (6.2 %) developed lung inju-
ries, with microspheres present in the lungs on histopatholog-
ical analysis, informing the radiation pneumonitis diagnosis.
The median LSF, evaluated with 99mTc-MAA planar scan,
was 23.7 % (min.: 13.1; max.: 45.6) in patients with lung
injuries, with an estimated median lung radiation dose of
25 Gy .
The risk of lung injury associated with 90Y-loaded glass
microsphere injection was evaluated in a group of 58 patients,
each receiving a lung dose >30 Gy [35]. In total, 19 (33 %)
received a cumulative LD exceeding 50 Gy (mean LD:
75.7 Gy). No clinically relevant lung radiation pneumonitis
was observed, with asymptomatic radiological signs of lung
disease seen in only 19 %. This observation indicates that the
lung dose was overestimated when using planar 99mTc-MAA,
with acquisition obtained within 2 hours of administration.
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Several factors have been described as having a significant
impact on LSF evaluation.
The impact of scatter correction has been analyzed in
both phantom [35] and clinical studies [35, 36], with
the overall results revealing cases with no scatter cor-
rection to be associated with overestimated LSF. In the
phantom study, the LSF (calculated on planar images)
was 3.2±0.02 % when no scatter correction was used,
yet only 0.3±0.01 when it was. Similarly, the mean
LSF of three patients was 7.8±2.3 % without scatter
correction, yet only 3.6±2.5 with [35]. Another study
demonstrated a mean LD overestimation of 40 % when
b c
d e
aFig. 2 MAA and glass
miscrosphere uptake discrepancy
related to transient arterial
vasospasm. Patient with
multifocal neuroendocrine liver
metastasis with a 5 cm lesion of
segment 6. a) Contrast enhanced
CT. b) Tumor MAA SPECT
uptake with a Btumor/non tumor^
uptake ratio (T/NT ratio) of 0.77
for segment 6 lesion. c) Glass
microsphere 90Y bremstrahlung
SPECT/CT evidencing a better
tumor targeting with a T/NT ratio
of 3.3 for the same segment 6
lesion. The retrospective analysis
of the diagnostic angiography (d)
and the therapeutic one (e) shows
an arterial vasospasm (black
arrow) on the diagnostic
angiography with a poor tumoral
blush as against no vasospasm
and a good tumoral blush (white
arrow) on the therapeutic one
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using SPECT/CT without scatter correction in a cohort
of 71 patients (Yu et al., 2013).
The delay between 99mTc-MAA injection and image acqui-
sition has also been reported to lead to LSF overestimation
[36]. Mean LSF, measured within 1 hour of injection, was 9.3
±3.4 %, increasing to 22.1±5.5 % after 5 hours. This increase
was more than likely the result of 99mTc-MAA degradation,
along with an increase in circulating activities.
Recently, 99mTc-MAA SPECT/CT has been evaluated for
its use in LSF calculation. SPECT/CT enables a direct evalu-
ation of lung volume andmass, which can then be used for LD
calculation instead of the estimated mass of 1 kg. Yu et al. [37]
described an LD calculation based on 99mTc-MAA SPECT/
CT (LDSPECT) with both scatter and attenuation correction. A
lung area located within 2 cm of the diaphragm was excluded
in order to avoid misregistration due to breathing. Planar-
imaging-based lung dose (LDplan) was found to be significant-
ly higher than LDSPECT, with a mean LDplan / LDSPECT ratio of
3.8±4.0 for the 76 evaluated patients. Overestimation of LSF
when using planar imaging has been confirmed by Kao et al.
[38].
Lastly, due to the difference in size and density of MAA
particles compared to microspheres, the accuracy of 99mTc-
MAA in predicting microsphere LSF and dosimetry must be
fully assessed. One can safely assume that 99mTc-MAA causes
LSF overestimation due to the smaller size of the MAA par-
ticles. This point was suggested by Salem et al. [35] in their
study where no clinically relevant radiation pneumonitis was
observed in 53 patients who received a lung dose of over
30 Gy, as evaluated with MAA. This concept was further
confirmed by the Elschot et al. study [39], comparing LSF
evaluation based on either 99mTc-MAA or 166Ho-
micospheres. The LD values estimated on the basis of pre-
treatment diagnostic 166Ho-micosphere SPECT/CT (median:
0.02 Gy) were found to be significantly better predictors of the
actual LDs, calculated using post-treatment 166Ho-micosphere
SPECT/CT, compared to doses estimated on the basis of
99mTc-MAA SPECT/CT (median: 2.5 Gy) or planar 99mTc-
MAA (median: 5.5 Gy; p <0.001).
Evaluation of the tumoral dose and response
HCC and tumor dose
With the exception of one study’s negative results, those of the
five other available studies were quite concordant, clearly
demonstrating there to be a dose/response relationship
(Tables 1).
The study of Kucuk et al. [40], using resin microspheres in
a group of 19 patients, was the only negative outcome study in
the HCC setting. The response rate that they recorded at
3 months, defined according to RESIST 1.1 criteria, did not
significantly differ between hypoactive or hyperactive lesions,
recorded at 40 % and 58 %, respectively (p=0.51). However,
this study included no dosimetric evaluation; only a qualita-
tive evaluation of the MAA uptake.
Using the partition model, Ho et al. [33] were the first to
report a link between tumor dose and response. In this study,
involving 71 HCC patients treated with resin microspheres,
the response rate was 37.5 % for lesions with a tumoral dose
>225 Gy versus only 10.3 % if the tumoral dose was ≤225 Gy
(p <0.006). Nevertheless, overall survival did not statistically
differ depending on the cumulative tumoral dose (< or
≥300 Gy, p=0.35). In a second study evaluating the resin
microsphere method, Kao et al. [41] also reported interesting
findings, though this was a preliminary study and involved
only eight evaluable patients. Still, all the responding lesions
had received a tumoral dose >91 Gy. Owing to all the lesions
having responded to treatment, a threshold tumor dose could
not be clearly identified in this study.
Chiesa et al. [12] and Mazzaferro et al. [6] conducted stud-
ies using glass microspheres, with the former offering prelim-
inary results on 48 patients [12] and the latter offering full
results [6] on 52.
A clear dose/response relationship was identified using a
dosimetric evaluation based on BEDs at the voxel level. Non-
responding lesions had received a median tumor dose of only
199 Gy, compared to 431 Gy for the responding ones (p
<0.0001) [12]. For response prediction, defining a non-
responding lesion with a TD <257 Gy as the true negative
and responding lesion with a TD >257 Gy as the true positive,
the threshold tumor dose of 257 Gy exhibited a sensitivity of
85 % and specificity of 70 % [12].
In a preliminary study [27], our group also observed
a strong dose/response relationship in 36 patients with
58 evaluable lesions of relatively large size (mean size:
7.1 cm). The mean TD was 372.7±142.0 Gy for the 45
responding lesions and only 153.8±80.8 Gy for the 13
non-responding ones (p <0.0001). None of the lesions
receiving a TD below 205 Gy responded, whereas only
five receiving >205 Gy did not respond. This threshold
TD of 205 Gy was thus confirmed to be predictive of
response, with a sensitivity of 100 % and accuracy of
91 %. According to multivariate analysis, TD was the
only parameter that correlated with response (p=0.019).
In this study, TD also affected survival. Progression-free
survival (PFS) was only 5.2 months when the TD was
<205 Gy versus 14 months (p=0.0003) with higher
doses. Overall survival (OS) was 9 months when the
TD was <205 Gy versus 18 months (p=0.0322) with
a TD of 205 Gy or higher.
These findings, pertaining to a 205 Gy threshold TD and
correlation between TD and survival, were confirmed in a
recent study involving 71 patients [7], in which the concept
of a personalized dosimetric approach, including treatment
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intensification when necessary, was also described. The pa-
tients who received treatment intensification were adminis-
tered an ILD ≥150 Gy, contrasting with the 120±20 Gy de-
livered in the classical approach. In this concept, the HILD
was <120 Gy and the LD was typically <30 Gy for one treat-
ment or <50 Gy for several. In total, 38 % of patients received
treatment intensification. The response rates were significant-
ly higher with the personalized dosimetric approach than with
the standard dosimetric approach, recorded at 86 % versus
only 55 %, respectively (p=0.01).
This intensification concept appears to be of particular val-
ue for PVT patients. Personalized dosimetry, with treatment
intensification where necessary, has been described in a study
involving 41 PVT cases [42]. In this trial, 37 % of patients
received treatment intensification. A high response rate of
85 % was achieved without causing any increase in liver
Grade≥III permanent toxicity (6 % versus 12 % in the non-
boosted patients, ns). The TD was found to exhibit a highly
significant impact on OS, which was 4.3 months (3.7-5
months) versus 18.2 months (8.5–28.7 months) for patients
with a TD below 205 Gy or over 205 Gy, respectively (p=
0.005). Those with a TD ≥205 Gy and good PVT targeting
(n=36) exhibited an OS of 20.9months. The objective median
OS was not reached, though it was longer than 24.5 months
and significantly longer (p=0.0493) for the five patients who
underwent lobar hepatectomy.
Metastatic disease and tumor dose
Several studies have produced disappointing results in this
context, yet there are some methodological concerns that
could account for this (Table 2). For example, only MAA
uptake qualitative evaluation was reported on some occasions,
with nomention of type of dosimetric approach [43, 44]. Also,
the morphological response evaluation used was at times in-
appropriate, not including necrosis or hypervascularization
evaluation [43, 44], and the means of evaluating delay of
response was also insufficient, consisting of 4–6 weeks in-
stead of 3 months [19]. Five studies produced disappointing
results, four evaluating resin microspheres and one glass
microspheres.
Knesaureck et al. [45] reported a comparative study of
MAA and resin microsphere uptake in a group of 20 patients
(lesion size not available). A strong correlation was demon-
strated for some patients, while others showed poor correla-
tion, with Spearman’s rank values of between 0.451 and
0.818.
Wondergem et al. [23], also comparing MAA and resin
uptake in 225 hepatic segments, reported disappointing results
in 31 patients, primarily involving metastasis. Differences of
>10 %, >20 %, and >30 % in the mean activity per milliliter
was found in 68 %, 43 %, and 32 % of the 225 segments
analyzed, respectively. Tumor burden significantly influenced
Table 1 Studies with MAA based tumor dose evaluation in HCC
Kucuk [40] Ho [33] Kao [41] Chiesa [12] Garin [27] Garin [7]
Product resin resin resin glass glass glass
Dosimetry NAa MIRD MIRD MIRD with BEDs MIRD MIRD
Nb patients 19 71 10 52 36 71
Nb lesions NA NA NA 65 58 NA
Lesion size
(cm)
NA NA NA 5.6 7.1 7.1




















Number of radioembolization (%) NA 1 (77.9)
2 to 5 (22.1)








RECIST1.1 WHO RECIST1.1 EASL EASL EASL
Time of evaluation 6 w NA NA 3 m 3 m 3 m
Dose/response
relationship
NA YES Probablyb YES YES YES
threshold
dose (Gy)
NA 225 NA 257 205 205
Impact on survival NA NA NA NA YES YES
a Only a visual evaluation of MMAwas done
b All lesion with a TD>91 Gy responded but all evaluated lesions were responding
Nb = number, NA = non available, S = surgery, CE = chemoembolization, w = week, m = months
Eur J Nucl Med Mol Imaging (2016) 43:559–575 567
these differences, with smaller discrepancies observed for seg-
ment involvement >25 %.
The 2005 Dhabuwala et al. [44] study reported no correla-
tion between qualitative MAA uptake and response in 58 pa-
tients treated by resin microspheres. Furthermore, CT re-
sponse rates at 3 months did not, in fact, differ between pa-
tients with high MAA uptake (n=37) and those with equivo-
cal or lowMAA uptake (n=21). Nevertheless, tumor response
was only evaluated based on lesion size changes. In other
studies, the MAA and microsphere injections were not per-
formed in comparable situations, with angiotensin II injected
only prior to microsphere administration. Due to its recog-
nized capacity to increase tumoral vascularization [46, 47],
MAA was unable to accurately predict microsphere
biodistribution in this study.
In their large study involving 66 patients and 435
lesions, Ulrich et al. [43] evaluated the use of resin
microspheres and also found no correlation between
MAA qualitative uptake and response. The mean tumor-
al size was relatively small (3.4 cm), with response
evaluated solely using lesion size changes. At 3 months,
290 lesions were evaluable according to RECIST 1.1
criteria. In total, 22 % of the responding lesions
exhibited low MAA uptake and 21.7 % of the non-
responding lesions high MAA uptake.
Van de Wiele et al. [19] conducted another study, this time
using glass microspheres, and also found there to be no cor-
relation between the accuracy of MAA quantification and re-
sponse, as the responding lesions exhibited a mean micro-
sphere activity of 1.95 MBq/cc compared to 1.90 MBq/cc
for non-responding ones (p=0.92). However, response was
evaluated very early in their study, namely at 4–5 weeks, with
the mean lesion size being quite small (3.5 cm) and MAA
uptake very low, with a mean uptake of only 1.5 % per lesion.
This last finding clearly demonstrates the significantly differ-
ent vascular behavior of metastasis in comparison with HCC,
given that the mean reported MAA uptake in HCC was
32.8 % [27].
Two studies published positive data on this issue.
Flamen et al. [28] conducted a preliminary study evaluating
resin microspheres involving eight patients and 39 lesions
with a mean size of 5.7 cm. They reported a strong correlation
between the tumoral absorbed dose, evaluated on 99mTc-MAA
SPECT imaging, and the FDG PET response to 90Y-resin mi-
crospheres in colorectal metastatic disease using an appropri-
ate dosimetric approach, namely the Monte Carlo simulation.
Table 2 Studies with MAA based tumor dose evaluation in metastatic disease
Knesaurek [45] Wondergem [23] Dhabuwala [44] Ulrich [43] Van de Wiele [19] Flamen [28] Lam [48]
Product resin resin resin resin glass resin resin
Dosimetry NA a NA b NA c MIRD MIRD Monte
carlo
MIRD
Nb patients 20 31 58 66 13 8 25
Nb lesions NA 225 b NA 435 91 39 NA
Lesion size
(cm)
NA NA NA 3.4 3.5 5.7 NA
Prior therapy
(%)














NA NA NA NA NA YES NA





NA NA WHO RECIST1.1 FDG PET FDG PET RECIST1.1
Time of
evaluation
NA NA 2 m 3 m 4-5 weeks 6 weeks 3 m
Dose/response
relationship
NA NA NA NA NA YES YES
threshold
dose (Gy)
NA NA NA NA NA NA 44.2
Impact on
survival
NA NA NA NA NA NA YES
a visual assessment of MAA and microspheres in tumors
b quantification of MAA and microspheres in hepatic segment
c visual evaluation of MAA uptake
Nb = number, NA = non available, Chemo = chemotherapy, m = months
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The median simulated absorbed dose was 20 Gy for the 20
poorest responding lesions and 46 Gy for the 19 responding
ones (p <0.001).
More recently, Lam et al. [48] reported very interesting
results involving 25 metastatic patients treated by resin micro-
spheres. In order to avoid bias, only those with identical MAA
and microsphere injection sites, as well as no injection fail-
ures, were analyzed, with response evaluated at 3 months ac-
cording to the RECIST 1.1 criteria. Their chosen approach
was original, based on both MAA scintigraphy and 99mTc-
sulfur colloid (SC) liver scintigraphy for the segmentation
between tumor and surrounding liver tissue. Furthermore,
the authors used and tested different fixed thresholds for both
MAA and SC volume delineation. This consisted of tumor
and healthy liver segmentation, with the aim of suppressing
manual segmentation, which would be of particular interest in
cases of multifocal disease, just as that encountered in meta-
static ones. Their dosimetric approach was based on the
MIRD concept. The mean TD was 82.7±23.9 Gy for re-
sponders versus 31.0±10.9 Gy for non-responderp (p
<0.001). A threshold tumoral dose of 44.2 Gy correlated with
response (p <0.001). The authors made a very interesting ob-
servation that the TD exhibited a clinical impact on survival.
The median OS of patients who received a TD of over 55 Gy
was 32.8 months, whereas those who received less than 55 Gy
had a median survival of only 7.2 months (p <0.05). The TD
was the only parameter that correlated with survival (p <0.01).
Evaluation of healthy injected liver dose (HILD)
and toxicity (Table 3)
Toxicity evaluation
When discussing liver toxicity, the three following factors
should be carefully considered: its imputability, severity, and
reversibility.
The imputability of a therapeutic agent in the event of side
effects is not always easy to demonstrate. This is typically true
for radioembolization, where imputability rules have yet to be
defined, since this context may involve a great number of
confounding factors, such as tumor progression, underlying
liver disease and severity, as well as previous or concomitant
chemotherapy.
The severity of an adverse event is usually graded using the
Common Terminology Criteria for Adverse Events (CTCAE).
For each study, the version used must thus be specified. In
cases involving cirrhosis, significant liver toxicities are often
encountered at baseline prior to therapy, and only an increase
in the toxicity score should thus be reported as an adverse
event potentially caused by treatment.
The third point that has been fairly widely discussed is the
potential reversibility of the toxicity. The reversibility of tox-
icities is not evaluated in the CTCAE. In cases of liver toxicity,
reversibility is common owing to liver tissue’s ability to re-
generate. As a result, severe but transient toxicities are not
necessarily limiting or life threatening. For example, when
lymphoma is treated by polychemotherapy, transient Grade
3 or 4 bone marrow toxicity almost always occurs, and
polychemotherapy is still the standard of care for lymphoma
patients.
Radiation-induced hepatic toxicity syndromes
Known to be associated with external beam radiotherapy, the
most common syndrome of liver toxicity is radiation-induced
liver damage, or RILD, first described many years ago [51].
This syndrome is secondary to damage to the centrilobular
vein and is commonly associated with ascites without jaun-
dice and elevated alkaline phosphatase, or less frequently,
transaminase enzymes.
The typical liver toxicity syndrome associated with
radioembolization is radioembolization-induced liver dam-
age, or REILD, recently described for the first time by Sangro
et al. [50]. REILD is typically associated with ascites, jaun-
dice, bilirubin elevation, a variable elevation of γGT and al-
kaline phosphatase, and virtually no change in transaminase
enzymes.
The exact toxicity syndrome can be more difficult to assess
for patients undergoing chemotherapy or chemotherapy-
radioembolization combined therapy prior to treatment, as
chemotherapeutic agents can also cause hepatic toxicities,
such as hepatic failure, cholestasis, or veno-occlusive disease.
The precise underlying cause of toxicity in these contexts,
either attributed to chemotherapy or radioembolization, is im-
possible to define, and combined toxicity can occur in cases
involving combined treatments.
Here, again, several confounding factors may be en-
countered, such as the presence and severity of under-
lying liver disease, previous therapy, concomitant thera-
py (especially for metastasis), definition of toxicity, var-
ious dosimetric approaches, different products, as well
as volume of irradiated liver and non-irradiated liver
(hepatic reserve).
This last factor, the hepatic reserve, is of great significance.
One study reported a Grade 3/4 liver toxicity rate of 82 % in a
whole-liver approach, compared to only 12 % (p <0.05) in a
group of patients without cirrhosis treated by resin micro-
spheres [52]. In another study, liver toxicities were observed
solely in cases involving whole-liver injection, but never in
those consisting of lobar injection [50].
On the other hand, a hyper-selective (segmental) approach
can be taken using high doses with low toxicity profile. The
concept of radiation segmentectomy was first described by
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Riaz et al. [53], using a high mean dose in the treated segment
(521 Gy; no HILD evaluation), who reported only 9 %
exhibiting Grade 3/4 biochemical toxicities [53]. When com-
paring this with large-scale hepatectomy, theoretically no
acute liver dysfunction should occur, regardless of the irradi-
ated liver dose (or HILD), provided that the hepatic reserve is
sufficient.
The last point that should be remembered is the de-
lay between toxicity occurrence and therapy, especially
for patients with cirrhosis, where the chronic liver dis-
ease can worsen regardless of the treatment adminis-
tered, if any at all. With radiation therapy, it is well
recognized that toxicity can be acute or delayed. In
general, however, only acute toxicity is reported with
the use of drugs, beginning in the first month of initi-
ation. This is despite the known possibility of delayed
toxicities, which, though less common than the toxic-
ities frequently reported in association with radiation
therapy, are still a considerable risk. This point is of
great interest when comparing the toxicities of
radioembolization to those of systemic drugs, such as
sorafenib or chemotherapy.
Several studies have analyzed liver dosimetry
and toxicity in HCC, all using glass microspheres
Liver toxicity frequency in HCC and predisposing factors
The frequency of liver toxicity, regardless of its severity, can
reach as high as 96 % in terms of transaminase levels in pa-
tients treated with glass microspheres, as shown in a whole-
liver approach in the Dancey et al. study [54]. In the same
study, however, severe transaminase toxicities occurred in on-
ly 23 % of the patients, underlying the need for an accurate
severity scoring.
In the Salem et al. study, involving the largest HCC patient
cohort, the rate of severe liver toxicities with glass micro-
spheres was found to be quite low, with Grade 3/4 bilirubin
toxicity observed in 19 % of 291 patients [3], though this was
a conservative analysis, since patients with pre-existing labo-
ratory toxicities were counted as toxicities at follow-up, even
if there was no change in grade. No clinically relevant hepatic
toxicity was reported by Hilgard et al. in their cohort of 108
patients [5]. Mazzafero et al. reported clinically detectable
ascites in 7.7 %, altered bilirubin (≥G3) in 13.5 %, and
Table 3 Studies with MAA based healthy injected liver dose evaluation and toxixity
Youn [44] Garin [7] Chiesa [12] Gulec [49] Sangro [50] Lam [48]
Number of patients 41 71 52 40 45 25
Product glass glass glass resin resin resin
Indication HCC HCC HCC Metastases : 87.5 %
HCC : 12.5 %
Primary : 28.9 %
Metastases : 71.1 %
metastases
Approach lobar lobar lobar Whole liver Whole liver : 73.3 %
Lobar : 26.7 %
Whole liver
Cirrhosis and severity Yes Yes
Child A: 94 %
Child B: 6 %
Yes
Child A: 83 %
Child B: 17 %
no no no



















no no no no 29.9 % no
Definition of toxicity CTCAE V3 CTCAE V3 Liver decompensation Liver failure REILD CTCAE V4
Severity G3 G3 and permanent any Clinically relevant any 50 % increase
of ALT, AST
and ALP




NA NA NA No, but no related
tocicity



















>66 Gy, CP of
33 %
HILD till 99Gy is
well tolerated
NA NA
HILD = healthy injected liver dose
HR = hepatic reserve (% of non irradiated liver), NTCP = non tumoral complication probability, CP = complication probability, ALT = alanine
aminotransferase, AST = aspartate aminotransferase, ALP = alkaline phosphatise, S = surgery, CE = chemoembolization, Chemo = chemotherapy
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alkaline phosphatase elevation (≥G3) in 11.5 % of their pa-
tients at 3-month follow-up. The liver decompensation rate at
3 months was 23.1 %, defined as the occurrence of any of the
following conditions: clinically relevant ascites, total bilirubin
>3 mg/dL, hepatic encephalopathy, prothrombin time interna-
tional normalized ratio >2.2 or variceal hemorrhage [6]. In this
study, the definition of liver toxicity was also conservative,
given that a clinically relevant ascites level could be classed
as CTCAE V3 Grade 2, dictating that only medical treatment
was required, or Grade 3, indicating the need for ascites punc-
ture. Clinically relevant ascites can be transient, as reported
elsewhere in the literature.
Lastly, permanent severe Grade ≥3 liver toxicities (CTCAE
V3) were reported in 8.4 % of a 71-patient cohort [7].
Predisposing factors besides dosimetry, such as the tumor
type (infiltrative or not), tumor volume (>70 %), elevated
basal transaminases (≥5 N), elevated basal bilirubin (≥2 mg/
dL or 34mmmol/L) or a combination of tumor volume ≥50 %
with albumin level <30 G/L, [55] have already been described
as having an impact on toxicity. In this study, the risk of major
liver toxicity related mortality was 18 % for patients present-
ing with at least one of these five prognostic factors, in com-
parison with 0 % for those exhibiting none. Underlying severe
biliary disease and PVT without MAA targeting have also
been reported to be predisposing factors of severe permanent
liver toxicity on multivariate analysis [7].
Liver toxicity and healthy injected liver dose evaluation
in HCC (Table 3)
Young et al. [49] were the first to report a statistically signif-
icant difference in median cumulative dose to the injected lobe
(ILD) between patients with or without toxicity in a group of
20 Okuda 1-classified HCC cases. An ILD of 222 Gy had
been administered to the patients with no toxicity, compared
to 390 Gy to those with (p <0.005). The reported toxicities
were only biological in nature and all were≥G3 (CTCAEV3).
For patients with liver toxicities, the median ILD was signif-
icantly higher in the Okuda 1-classified patients than the
Okuda 2 ones (390 Gy and 199 Gy, respectively, p <0.05).
These findings underline the impact of the clinical baseline
status on liver tolerance. No evaluation of the healthy injected
liver lobe dose (HILD) was performed in this study.
The HILD was recently evaluated in a study [7], where the
mean dosimetric evaluation was performed as standard using
the MIRD approach on a cohort of 71 carefully selected pa-
tients, 94.4 % of whom had a Child Pugh score of A. The
injected activity, ILD, HILD, and hepatic reserve did not cor-
relate with severe (CTCAE V3, G ≥3) clinical permanent liver
toxicity. The absence of correlation between the HILD and
hepatic toxicity can be accounted for by the amount of hepatic
reserve. Only the association of a HILD >100 Gy (and
>120 Gy) with a hepatic reserve <30 % correlated with severe
permanent liver toxicity on univariate analysis. On multivari-
ate analysis, only the association of a HILD >120 Gy with a
hepatic reserve <30 % remained correlated with severe per-
manent liver toxicity. A liver toxicity score has since been
proposed, taking into account several parameters, including
the association of a HILD >120 Gy with a hepatic reserve
<30 % (Table 4). A score ≥3 was predictive of severe perma-
nent liver toxicity with a sensitivity of 83 % and overall accu-
racy of 97 % [7].
In a recent study, Chiesa et al. [12] calculated the global
dose to the healthy liver, including to the irradiated and non-
irradiated parenchyma. This parameter is still currently used in
practice, particularly valuable in external beam radiation ther-
apy, as both lobes typically receive a varying amount of radi-
ation due to the use of multiple irradiation beams.With the use
of this parameter, normal tissue complication probability
(NTCP) can then be calculated. Chiesa et al. found that the
risk of liver decompensation (as defined by Mazzaferro et al.
[6]) was 0 %, 14 %, 40 %, and 67 % for global healthy liver
dose intervals of 0–35 Gy, 35–70 Gy, 70–105 Gy, and 105–
140 Gy, respectively [24]. The authors suggested fixing a limit
of 70 Gy for the global healthy liver dose, a concept validated
in one particular case where, corresponding to an NTCP of
approximately 15 % of liver decompensation, glass micro-
spheres were implanted 3.75 days after the calibration date,
corresponding to a defined specific activity.
The use of this NTCP model in radioembolization must be
clinically assessed, especially in cases involving unilobar in-
jection, as it has been validated for external beam radiotherapy
in a specific configuration of irradiation, especially in terms of
Table 4 Liver Toxicity Score (LTS)
Variables score
HILD>120 Gy and hepatic reserve <30 %. 0 or 3
Main PVT without MAA targeting 0 or 3
Severe underlying biliary disease 0 or 3
ALT level >5 N 0 or 1
Bilirubin level>35 μmol/mL 0 or 1
Tumoral involvement >70 % 0 or 1
Child B 0 or 1
Previously treated patients 0 or 1
Patient LTS 0 to 14
For each variable: 0 point is attributed if it is absent and 1 or 3 points are
attributed if present
The patient score is obtained by adding the number of points attributed to
each variable
The score is considered positive (predictive of liver toxicity) if its value
is≥3
The LTS was designed to predict, prior therapy, the risk of liver failure. A
score≥3 was predictive of severe permanent liver toxicity with a sensi-
tivity of 83 %, i.e., only one toxicity missed, and overall accuracy of
97 %.
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dose rate , that differs from that encountered in
radioembolization. For example, for a patient with unilobar
injection, namely where one lobe receives no irradiation,
who exhibits a hepatic reserve of 50 %, it is more than likely
that no matter what amount of total healthy liver dose is re-
ceived, the treatment will be well tolerated due to this high
hepatic reserve, especially in comparison to surgery.
For metastatic disease, studies analyzing liver toxicity
and dosimetry are extremely scarce (Table 3)
All these studies were performed using resin microspheres.
Cases of metastatic disease present more difficulties in ana-
lyzing toxicity and dosimetry, as most patients have typically
received either limited or no treatment, or a combination of
chemotherapy and radioembolization.
Liver toxicity frequency in metastatic disease
and predisposing factors
In a multicenter international collaboration, Kennedy et al.
[22] reported the outcome of 680 treatments with resin micro-
spheres for non-resectable hepatic tumors, primarily metasta-
ses (86 %). This is the largest cohort of its kind described to
date, with chemotherapy used prior to treatment in 66 % of
cases.
The authors evaluated the risk of liver toxicity, using the
term REILD. REILD-related death was described in 28 of 680
treatments (4 %), with 21 occurring in one particular center
that used the empirical method. HILD was not evaluated in
this study, though several factors were identified as correlating
with RIELD, such as activity delivered (p <0.0001) or pre-
scribed (p <0.0001), percentage of empiric activity delivered
(p <0.0001), number of prior liver treatments (p <0.0008),
medical center (p <0.0001), and treatment of the right lobe
(p=0.0008).
In the Sangro et al. study, REILDwas diagnosed in 20% of
the patients (i.e., ten cases out of 45) who received resin mi-
crospheres [50]. Three cases were severe and resulted in death.
REILD was only observed in patients who had received prior
chemotherapy and in those undergoing whole-liver treatment
(vs. lobar). In addition, the authors identified several other
predisposing factors for liver toxicity in patients receiving
whole-liver radioembolization, including HCC diagnosis
(p=0.002), flow redistribution during angiographic procedure
(p=0.004), and activity administered relative to total-liver vol-
ume (p=0.003).
Liver toxicity and healthy injected liver dose evaluation
in metastatic disease
Using the partition model, Gulec et al. [56] were the first to
evaluate HILD, treating 40 patients who were primarily
metastatic disease cases with resin microspheres in single
whole-liver administration. The mean HILD was 17.2 Gy
(min.: 0.7; max.: 99.5 Gy). No liver toxicity was observed in
this study and the authors concluded that the healthy liver
tissue tolerated doses of up to 99.5 Gy.
The mean HILD was also evaluated using the partition
model in the Sangro et al. study [50], involving 31 patients
receiving whole-liver radioembolization. This value differed
significantly (p=0.02) between the REILD (36.7 Gy) and
non-REILD groups (25.7 Gy).
Lam et al. recently published interesting results for their
study using a dosimetric approach based on MIRD and a
fusion MAA SPECT/SC SPECT for the segmentation be-
tween tumors and healthy liver tissue [48]. The trial involved
25 patients with colorectal metastases treated with a lobar
approach. They all had received heavy previous treatment
and only three underwent systemic therapy following
radioembolization. The authors reported a correlation (r=
0.38-0.69; p <0.01) between the HILD and change in serum
liver enzymes (aspartate aminotransferase [AST], alanine
transaminase [ALT], and alkaline phosphatase). The HILD
was found to be an accurate predictor of broad biochemical
toxicity, defined as a 50 % increase in each of the three liver
enzymes, given that all were increased at doses ≥24.5 Gy. No
toxicity higher than CTCAE V4 Grade 1 was observed for
these enzymes.
Post-therapeutic bremsstrahlung or PET dosimetry
Post-therapeutic dosimetry is believed to be more accurate
than MAA dosimetry due to its capacity to evaluate the true
dose corresponding to the real distribution of the therapeutic
agent, rather than the estimated dose based on the distribution
of a surrogate measure. Post-therapeutic dosimetry is thus
required to define, as precisely as possible, the tumoral thresh-
old doses and liver maximal tolerated dose.
Post-therapeutic dosimetry cannot be used for a selected
patient to adapt the treatment schedule, such as in an attempt
to optimize the activity that has to be injected in order to reach
the tumoricidal dose while not exceeding the maximal toler-
ated liver dose. However, post-therapeutic dosimetric evalua-
tion does provide the effectively received doses and thus con-
firms the MAA findings.
The most relevant study assessing post-therapeutic dosim-
etry was published by Strigari et al. [14]. The authors investi-
gated dose distribution using post-treatment (3-dimensional)
bremsstrahlung activity distribution and Monte Carlo dose
voxel kernel calculations. The mean doses to the tumors and
healthy injected liver were calculated for 73 HCC patients
treated with resin microspheres. The toxicity was graded using
the CTCAE V4. The median HILD was 36 Gy (range: 6–
78 Gy), and Grade ≥2 (G2), ≥3 (G3), and ≥4 (G4) liver tox-
icities were observed in 32% (23/73), 21% (15), and 11% (8)
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of patients, respectively. A healthy injected liver dose of
52 Gy (95 % CI: 44–61 Gy) was identified in a whole-liver
injection, providing a 50% probability of≥G2 liver toxicity in
this patient group.
Post-therapeutic PET dosimetry has also been described as
technically possible due to a small probability of positron
emission in the 90Y decay [57]. Several studies have provided
evidence that 90Y PET is superior to 90Y bremsstrahlung for
tumors and non-target tissue detection (especially for the
stomach) and dosimetry [58].
In one study, 90Y PET dosimetry was available for four
patients with gastroduodenal resin microsphere uptake [30].
One patient with a mean gastric dose of 18 Gy remained
asymptomatic, while the remaining three, having received
gastric or duodenal doses ≥49 Gy, suffered from gastritis or
duodenitis.
Perspectives
Prospective trials with bothMAA and post-therapeutic dosim-
etry must now be performed to confirm these preliminary
results observed retrospectively, and in order to obtain the
most valuable evaluation of tumoral threshold dose and max-
imal liver tolerated dose. Such an evaluation should take into
account all potential confounding factors, such as indication,
tumor size, product used, and so on, to avoid bias and errone-
ous conclusions.
Due to the concordant results found in HCC patients, a
personalized dosimetric approach using MAA should be im-
plemented in the near future. For metastatic disease, more
studies must be carried out before we are able to define a more
personalized approach, as the results are more contradictory in
this context.
Conclusion
99mTc-MAA SPECT/CT-based dosimetry is of major interest
in radioembolization conducted with radiolabeled micro-
spheres. This method enables accurate patient selection, ex-
cluding patients with high risk of lung shunting from therapy,
while the quantification of lung shunting can be further opti-
mized. 99mTc-MAA SPECT/CT-based dosimetry has brought
to light a clear dose/response relationship in HCC patients in
various independent studies. There have been contradictory
results published in the metastatic disease context, with the
more recent results providing the most value. A correlation
between tumor dose and overall survival has also been dem-
onstrated. The possibility of achieving a personalized dosi-
metric technique has now been advanced. Calculating the
healthy injected liver dose and predicting toxicity are still
highly challenging processes, despite several studies having
demonstrated a high correlation between liver toxicities and
HILD or other parameters related to whole-liver dose, as well
as between liver toxicities and a combination of HILD and the
hepatic reserve. If such a personalized approach becomes pos-
sible on account of these advances, it could have a significant
clinical impact. 99mTc-MAA SPECT/CT must be more exten-
sively studied and is certain to benefit from future improve-
ments, such as dose volume histogram generation, BEDs, and
eventually, more complex approaches like the Monte Carlo
simulation and dose kernel point evaluation.
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